The companies have identified an initial set of genetic biomarkers to predict drug response and will validate the findings in ...

The Shenzhen, China-based biotech plans to launch a Phase I trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IN026.

BobcatBio brought on the contract development and manufacturing organization to support manufacturing for ongoing Phase I studies in lymphoma and solid tumors.

The government hopes to limit cases in which NICE determines a treatment isn't cost effective after the MHRA has deemed it ...

In its third phase, the Diagnostics Accelerator will support the development of multi-marker panels leveraging digital and AI tools that can accelerate precision treatments.

Early clinical data indicates the treatment leads to dose-dependent increases in functional AAT protein, which is altered in the condition.

BriGene Biosciences supported Grit with technology transfer, manufacturing, and regulatory requirements for the IND for GT307.

A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.

Last week, the company got the FDA's tentative approval for the radioligand therapy, but a judge may soon decide whether it's ...

The firm originally submitted the application seeking approval for TLX101-Px in August 2024, but the agency requested additional efficacy analysis.

Sarepta plans to evaluate the gene therapy with a new immunosuppressive regimen in the hopes of relaunching it in the non-ambulatory indication.

The company's clinical development plan comprises three global Phase III studies, including two focused on infants and a third for older patients.